Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-TCR-T Cells for CMV Infection After HSCT
NCT04153279Phase 1Completed
- Sponsor
- Lu Daopei Hospital
- Start
- Dec 2019
- Primary completion
- Nov 2022
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CMV-TCR-T cells in cytomegalovirus infection (CMV), sponsored by Lu Daopei Hospital. Primary endpoint: Percentage of adverse events at 3 months. Started Dec 2019; status: completed.
02
Drugs
CMV-TCR-T cells
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04153279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153279.